Off-label prescribing in pregnancy: A case of risky business or business as usual?

Research output: Contribution to journalEditorial

3 Citations (Scopus)

Abstract

The licensing of medications for use in pregnancy represents a double edged sword in need of urgent attention. While product licences are important in instilling some sense of confidence that a medication meets stringent tests of efficacy and safety in the management of a specific condition in a specific population, they remain subject to significant limitations and biases. Given the commercial nature of the pharmaceutical industry, many would consider that product licensing is not just solely reflective of a medication passing a regulatory benefit-risk analysis, but also a more stringent internal profit-loss analysis.
Original languageEnglish
Pages (from-to)78-79
Number of pages2
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Volume187
DOIs
Publication statusPublished - Apr 2015
Externally publishedYes

Keywords

  • medications during pregnancy
  • medico-legal concerns

Fingerprint Dive into the research topics of 'Off-label prescribing in pregnancy: A case of risky business or business as usual?'. Together they form a unique fingerprint.

Cite this